Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.
Image Use Agreement
By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.
Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.
You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.
IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.
You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.
Pacific Biosciences Releases New Software and Chemistry for Sequel System
Thursday, August 4, 2016
MENLO PARK, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB) today announced it has released a set of key updates for the Sequel™ System, the company’s latest product based on its Single Molecule, Real-Time (SMRT®) Sequencing technology. The new release provides performance improvements via updated sequencing chemistry, optimized sample clean-up protocols, and associated software that together further improve read lengths, throughput and accuracy of the system. In addition, as customers upgrade their Sequel Systems to the new software and chemistry, they will no longer be subject to the supply constraints for SMRT Cells that were in effect earlier this year.
“These updates reinforce our continued commitment to improving SMRT Sequencing throughput, read length, and accuracy through optimized protocols and chemistry to enhance applications, such as de novo assembly, targeted sequencing, and the Iso-Seq™ method for RNA analysis,” said Kevin Corcoran, Senior Vice President of Market Development for Pacific Biosciences. “With this release, we have removed SMRT Cell supply constraints as we begin to source SMRT Cells for the Sequel System from our high-volume supplier.”
Yi Han, Ph.D., Assistant Professor in the Department of Molecular and Human Genetics at Baylor College of Medicine, who had early access to the new chemistry and software commented: “We are very impressed with the data we are getting with the latest update to the Sequel chemistry, sample prep, and software. As one of the first adopters of SMRT Sequencing, we appreciate how PacBio has partnered with us since 2010 to continually make improvements to the technology that directly benefit our research.”
Robert Sebra, Ph.D., Director of Technology Development & Associate Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai stated, “To date we’ve successfully demonstrated high molecular depth targeted long-range amplicon sequencing for a variety of medically relevant and other research applications, in addition to using the Iso-Seq and variant validation pipelines on Sequel. With the most recent releases, we’ve now seen significantly improved sequencing metrics and the non-restricted SMRT Cell supply will now enable larger genomes to be sequenced, and research requiring extreme molecular depth using the Sequel technology to truly differentiate the power of higher throughput long-read single molecule sequencing.”
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future availability, uses, quality or performance of, or benefits of using, products or technologies, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.